Gout is an ancient disease. As early as the Babylonian period, gout was one of the most prevalent diseases at that time. It was also called "the disease of kings" and "the disease of kings" because of its frequent occurrence in the court and among the dignitaries.
Many patients with diabetes are painless when their blood sugar is high, and retinopathy is also silent and imperceptible. Therefore, the majority of diabetes patients should be reminded that after the diagnosis of diabetes, they must regularly screen the sugar network, and early diagnosis and treatment is the key. Early detection, early treatment and regular reexamination can avoid more than 90% of severe visual impairment.
The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.
The European Union has recently approved Roctavian, the first gene therapy for haemophilia A. The therapy has led to a significant reduction in the average number of annual bleeds and the average number of annual clotting factor VIII transfusions in patients with this severe bleeding disorder, and has a good safety profile.
The US FDA has approved pemigatinib, the first targeted drug to date for patients with specific mutated blood tumours, and the results of the study show that the drug made tumours disappear completely in 79% of patients!
Research suggests that gender-related differences in lung cancer survival are largely determined by known prognostic factors, suggesting an opportunity to explore gender differences in treatment preference, choice and accessibility.
Recently, the US FDA has granted orphan drug status to two new therapeutics in a row. One is a small molecule inhibitor, PCLX-001, for the treatment of acute myeloid leukaemia; the other is a T-cell therapy, ET140203, for the treatment of hepatoblastoma. Both therapies are currently in relevant trials.
A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!
New research confirms that the innovative treatment Zolbetuximab, in combination with chemotherapy, is highly effective in the treatment of gastric cancer, especially in advanced stages, and is expected to be a potential new treatment for patients with gastric cancer.
The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours
